Division of Samsung Electronics Co. Ltd.
Latest From Samsung BioLogics
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
The latest oncology development news and highlights from our US FDA Performance Tracker.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Samsung-Quintiles joint venture
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Samsung Electronics Co. Ltd.
- Senior Management
Tae Han Kim, PhD, CEO
Dongjoong Kim, CFO
- Contact Info
Phone: 2 2255 8500
300 Songdo Bio Way
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.